Patents Examined by Karen Cheng
  • Patent number: 10851066
    Abstract: The compound 2-(3-tert-Butylphenyl)-4,6-difluoro-1H-benzo[d]imidazole and its use are disclosed: The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: December 1, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel D. Banister, Edgar Engleman, Khoa D. Nguyen, Mark Smith
  • Patent number: 10851073
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 1, 2020
    Assignee: AbbVie Inc.
    Inventors: Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym
  • Patent number: 10836719
    Abstract: An object is to provide a method for easily producing maleimide (MI) in which trace amounts of residual acid components as impurities in a crude MI are efficiently reduced, that is, the acid value is sufficiently reduced. <1> A method for producing purified MI, comprising reducing an acid value of crude MI by 50% or more, by adding carbodiimide (CDI) to a solution comprising the crude MI to react an acid component in the crude MI with the CDI. <2> The method for producing purified MI, comprising adding 0.5% by mass or more and 8% by mass or less of the CDI with respect to a mass of the crude MI for reaction. <3> The method for producing purified MI, wherein the CDI is N,N?-diisopropyl carbodiimide (DIC). <4> The method for producing purified MI, comprising removing a urea derivative of the CDI (CDI-U) by-produced when reacting the acid component in the crude MI with the CDI.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 17, 2020
    Assignee: UNITIKA LTD.
    Inventors: Yuki Yamada, Tatsuya Morikita, Yosuke Sugimoto, Takeshi Yoshida, Akira Shigeta, Yoshiaki Echigo
  • Patent number: 10836780
    Abstract: A polyfluoroalkyl phosphoric acid ester represented by the general formula [CnF2n+1(CH2CF2)a(CF2CF2)b(CH2CH2)cO]mP(O)(OH)3?m [I] n: 1 to 6, a: 1 to 4, b: 1 to 3, c: 1 to 3, m: 1 to 3) or a salt thereof. The polyfluoroalkyl phosphoric acid ester represented by the general formula [I] is produced by subjecting a polyfluoroalkyl alcohol represented by the general formula CnF2n+1(CH2CF2)a(CF2CF2)b(CH2CH2)cOH [II] (n: 1 to 6, a: 1 to 4, b: 1 to 3, c: 1 to 3) to a dehydration condensation reaction with phosphoric acid. The polyfluoroalkyl phosphoric acid ester can be easily synthesized without passing through dialkyl ester as in the case of phosphonic acid, and used for a mold-releasing agent comprising the same or a salt thereof as an active ingredient.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 17, 2020
    Assignee: UNIMATEC CO., LTD
    Inventors: Yuichiro Oda, Yoshiyama Kaneumi
  • Patent number: 10821100
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 3, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Patent number: 10793581
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: October 6, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Hyeong-wook Choi, Silvio Campagna, Steven Mathieu
  • Patent number: 10793560
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: RedX Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • Patent number: 10793562
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 6, 2020
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • Patent number: 10774078
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 15, 2020
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 10774059
    Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 10765662
    Abstract: The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 8, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10759789
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: September 1, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Patent number: 10759746
    Abstract: The present invention relates to a hydrated crystalline form of 2-acrylamido-2-methylpropane sulfonic acid having a 2-theta powder X-ray diffraction diagram comprising peaks at 10.58°, 11.2°, 12.65°, 13.66°, 16.28°, 18.45°, 20°, 20.4°, 22.5°, 25.5°, 25.88°, 26.47°, 28.52°, 30.28°, 30.8°, 34.09°, 38.19°, 40.69°, 41.82°, 43.74°, 46.04° degrees (+/?0.1°). The present invention also relates to a production method for this form of 2-acrylamido-2-methylpropane sulfonic acid and a preparation method for an aqueous solution A of a salt of this form of 2-acrylamido-2-methylpropane sulfonic acid, and the (co)polymer of this form of -acrylamido-2-methylpropane sulfonic acid.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 1, 2020
    Assignee: S.P.C.M. SA
    Inventors: Cédrick Favero, Johann Kieffer
  • Patent number: 10745378
    Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: August 18, 2020
    Assignee: Mycovia Pharmaceuticals, Inc.
    Inventors: William J. Hoekstra, Christopher M. Yates
  • Patent number: 10729684
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 4, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Karina R. Vaida
  • Patent number: 10730829
    Abstract: The present invention relates to a novel compound exhibiting anti-oxidative or anti-inflammatory activity, a method of preparing the compound, a pharmaceutical composition for preventing or treating inflammatory diseases or the diseases caused by oxidation, which comprises the compound or a salt thereof as an active ingredient, and an anti-inflammatory or anti-oxidative cosmetic composition or food composition.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: August 4, 2020
    Assignee: University-Industry Cooperation Group of Kyung Hee University
    Inventors: Young Pyo Jang, Sang Cheol Park
  • Patent number: 10723758
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 28, 2020
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 10722521
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: July 28, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Patent number: 10696661
    Abstract: Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 30, 2020
    Assignee: Exonate Limited
    Inventors: David Bates, Jonathan Morris, Hamish Toop, Jennifer Batson, Andrew David Morley